Opinion

Video

Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer

Author(s):

Lawrence Karsh, MD, FACS,Stephen J. Freedland, MD

Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.

Video content above is prompted by the following:

  • What insights do data show regarding GnRH agonists and GnRH antagonists and cardiovascular outcomes? If a patient has prior CVD, should they be treated with a GnRH antagonist?
Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Channing J. Paller, MD, answers a question during a Zoom video interview
Vanita Gaglani, RPT, answers a question during a video interview
Channing J. Paller, MD, answers a question during a Zoom video interview
Related Content
Man talking with doctor | Image Credit: © rocketclips - stock.adobe.com
February 19th 2025

WOLVERINE findings highlight benefits of MDT in oligometastatic prostate cancer

Benjamin P. Saylor
Median PFS was 35 months in the MDT plus SOC group vs 21 months in the SOC alone group.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Prostate cancer, 3D illustration showing presence of tumor inside prostate gland which compresses urethra | © Dr_Microbe - stock.adobe.com
February 14th 2025

Darolutamide plus ADT shows mHSPC benefit regardless of disease volume

Benjamin P. Saylor
"Efficacy outcomes with darolutamide plus ADT were improved vs placebo plus ADT regardless of disease volume," said Fred Saad, MD, FRCS.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 13th 2025

Darolutamide is safe, efficacious in mHSPC regardless of patient age

Benjamin P. Saylor
"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel regardless of age," said Joan Carles, MD, PhD.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | © Dr_Microbe - stock.adobe.com
February 13th 2025

Race subgroup analysis points to clinical benefit of darolutamide in nmCRPC

Benjamin P. Saylor
In both racial cohorts, median MFS was not reached in the darolutamide group.
© 2025 MJH Life Sciences

All rights reserved.